Who is sponsoring NCT06828380?

NCT06828380 is sponsored by National Cancer Center, Korea.

What drugs are being tested in NCT06828380?

Interventions in NCT06828380: Particle beam radiation therapy.

What condition does NCT06828380 study?

NCT06828380 studies Advanced Hepatocellular Carcinoma (HCC).

Is NCT06828380 still recruiting?

NCT06828380 is currently recruiting now. Last updated 26 December 2025.

Last reviewed 2025-12-26 · How we verify

NCT06828380: IOPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion

Recruiting now Phase 2 Last updated 26 December 2025

What this trial tests

Phase 2 trial testing Particle beam radiation therapy in Advanced Hepatocellular Carcinoma (HCC) in 128 participants. Currently enrolling.

Timeline

15 April 2025

Primary endpoint
6 August 2028

6 August 2028

Quick facts

Lead sponsor	National Cancer Center, Korea
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	treatment
Enrollment	128
Start date	15 April 2025
Primary completion	6 August 2028
Estimated completion	6 August 2028
Sites	2 locations across South Korea

Drugs / interventions tested

Particle beam radiation therapy

Conditions studied

Advanced Hepatocellular Carcinoma (HCC) — all drugs for Advanced Hepatocellular Carcinoma (HCC) →

Sponsor

National Cancer Center, Korea

Who can join

19 and older, any sex, with Advanced Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the present study, we aim to investigate the efficacy and safety of concurrent therapy of Immunotherapy based combination therapy and Radiotherapy in patients with advanced HCC showing macrovascular invasion.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Combining External Beam Radiotherapy and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
Le C, Abraham AG, Tankel K, Usmani N, et al · · 2026 · PMID 42041745 · DOI 10.3390/curroncol33040226
Mechanisms of Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma and Strategies for Reversal.
Dai XY, Yang XJ, Wu H, Lv YH, et al · · 2025 · PMID 41514551 · DOI 10.3390/cancers18010039

Verify or expand the search:

Other recruiting trials for Advanced Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07493044 — An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
NCT07500220 — Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC · Phase 1, PHASE2 · recruiting
NCT07123545 — Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT06902389 — A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07039201 — A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) · NA · recruiting

Other National Cancer Center, Korea trials

Trials by the same sponsor.

NCT07399561 — Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy · NA · not yet recruiting
NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation
NCT07171528 — Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer · Phase 2 · recruiting
NCT07125924 — Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer · NA · not yet recruiting
NCT07041515 — Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06828380 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Korea
Last refreshed: 26 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06828380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing